Effect of [1,3-di-n-butyl-7-(2-oxopropyl)-xanthine] (denbufylline), a low Km phosphodiesterase inhibitor, on striatal acetylcholine release in the rat: analysis using cerebral microdialysis.
Effect of oral and intraperitoneal administrations of [1,3-di-n-butyl-7-(2-oxopropyl)-xanthine] (denbufylline) on acetylcholine (ACh) content and release in the rat striatum was investigated. Denbufylline (3, 10 and 30 mg/kg, p.o.) decreased striatal ACh contents in a dose-dependent manner. Denbufylline administration (30 mg/kg, i.p.) produced no significant change in the spontaneous release of ACh, while it increased a high potassium-evoked ACh release in the striatum. These results suggest that denbufylline may be a drug inducing the increased release of ACh in the brain.
Katsura
M
M
Department of Pharmacology, Kyoto Prefectural University of Medicine, Japan.
Kuriyama
K
K
D000109:Acetylcholine / Q000378:metabolism*; D000284:Administration, Oral; D000818:Animals; D003342:Corpus Striatum / Q000378:metabolism*; D003956:Dialysis / Q000379:methods; D004305:Dose-Response Relationship, Drug; D008297:Male; D011188:Potassium / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D014970:Xanthines / Q000008:administration & dosage / Q000494:pharmacology*
D014970:Xanthines; C043898:denbufylline; D000109:Acetylcholine; D011188:Potassium